Roche Announces Positive Top-Line Results from Phase III COMMODORE 3 Study of Crovalimab in Chinese Patients with Paroxysmal Nocturnal Hemoglobinuria

On May 23, Roche announced that its innovative drug Crovalimab achieved positive results in the Phase III clinical study (COMMODORE 3) for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). The average proportion of hemolysis control measured by lactate dehydrogenase (LDH) levels, and the proportion of patients avoiding transfusion (TA), both reached the co-primary endpoints.

COMMODORE 3 is a multi-center, single-arm Phase III clinical study conducted exclusively in China, aiming to evaluate Crovalimab for the treatment of Chinese PNH patients who have not previously received complement inhibitor therapy. Detailed results will be announced at an upcoming medical conference.

PNH is a rare and fatal hematological disease, with an incidence of about 1 to 10 cases per million people. The majority of patients are young adults, and those aged 20 to 40 account for approximately 77%. Without treatment, the risk of death within five years is as high as 35%. Currently, in China, classic PNH is mainly managed with blood transfusions and symptomatic treatments, and there is still a lack of effective treatments targeting the underlying cause.

Crovalimab is a new-generation C5 inhibitor independently developed by Roche through the engineering transformation of continuous monoclonal antibody recycling technology (Smart-Ig). It can block the cleavage of complement C5 into C5a and C5b, with the potential to inhibit complement activation. The complement system is part of the human innate immune system, and complement activation is a cause of many diseases.

Source: PharmaCube